PACS Group (PACS) saw its stock price surge by 38.80% in pre-market trading on Thursday, following the release of its impressive third-quarter financial results, optimistic full-year projections, and the completion of its financial restatement. The healthcare operations company's performance significantly exceeded market expectations, triggering a wave of investor enthusiasm.

The company reported robust third-quarter figures, with quarterly revenue reaching $1.34 billion, marking a substantial 31.0% increase compared to the same period last year. This figure surpassed analyst estimates of $975.647 million by an impressive 37.86%. While earnings per share of $0.32 slightly missed the consensus estimate of $0.33, it still represented a remarkable 220% improvement from the previous year's $0.10 per share.

Investors were particularly encouraged by PACS Group's forward-looking statements. The company projects full-year 2025 revenue to be between $5.25 billion and $5.35 billion, with adjusted EBITDA expected in the range of $480 million to $490 million. This positive outlook, coupled with the company's strong Q3 performance, has bolstered confidence in PACS Group's growth trajectory.

Adding to the positive sentiment, PACS Group announced the completion of a restatement of its previous financial statements, bringing the company current with SEC filing obligations. This move has significantly enhanced investor trust in the company's financial transparency and governance. Furthermore, PACS Group's expansion strategy appears to be gaining traction, with its portfolio now including 320 healthcare operations across 17 states, ownership of 51 facilities, and purchase options on an additional 59 facilities. The company's commitment to growth through a combination of leasing, acquisitions, and evaluating opportunities in both high-performing and underperforming operations has clearly resonated with the market, contributing to the significant stock price surge.